EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Mathilde Marchand iD, Kenta Yoshida iD, Antonio Gonçalves iD, Rene Bruno iD, Chunze Li iD, Jin Y Jin iD, Pascal Chanu iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)

DOI: 10.1002/psp4.70304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 30.07.2026. Verfasst von Mathilde Marchand und 6 weiteren Autor:innen. Beteiligte Einrichtung: Certara Integrated Drug Development, Paris, France. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Neoplasms, Decision Support Techniques, Antineoplastic Agents. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oncology market is evolving, with an increasing number of therapeutic options making the inference of treatment benefit from early development critical. The “Go” versus “No Go” decisions from such trials usually rely on probabilities of achieving meaningful improvements (effect sizes) in endpoints like objective response rate, tailored to products' profile, supporting faster transitions to confirmatory trials. Operating characteristics are sensitive to methodological details, important for establishing an early decision framework for ungating a pivotal clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicNeoplasmsDecision Support TechniquesAntineoplastic AgentsHumansResearch DesignMedical Oncology

Stichwörter der Autor:innen

decision makingeffect sizeoperating characteristicstumor growth inhibition metrics

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Certara Integrated Drug Development, Paris, France.
  • Clinical Pharmacology, Genentech, South San Francisco, California, USA.
  • R&B Pharmacometrics, Marseille, France.
  • Clinical Pharmacology, Genentech-Roche, Lyon, France.

ORCID-Profile: Mathilde Marchand, Kenta Yoshida, Antonio Gonçalves, Rene Bruno, Chunze Li, Jin Y Jin, Pascal Chanu

Zitieren

APA

Marchand, M., Yoshida, K., Gonçalves, A., Bruno, R., Li, C., Jin, J. Y., & Chanu, P. (2026). Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70304

Vancouver

Marchand M, Yoshida K, Gonçalves A, Bruno R, Li C, Jin JY, et al. Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70304

BibTeX
@article{Marchand2026,
  author = {Marchand, Mathilde and Yoshida, Kenta and Gonçalves, Antonio and Bruno, Rene and Li, Chunze and Jin, Jin Y and Chanu, Pascal},
  title = {Refinement of Operating Characteristics for Model‐Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/psp4.70304}
}
Kostenlos starten →